Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17592627 | 1.00 | SMYD3 (0.33) | SMYD3CPB2 | |
| SCHEMBL17592558 | 1.00 | SMYD3 (0.33) | SMYD3CPB2 | |
| SCHEMBL5655242 | 0.88 | — | — | |
| SCHEMBL19103036 | 0.82 | NCF1 (0.38) | — | |
| SCHEMBL13246020 | 0.81 | — | — | |
| SCHEMBL16411251 | 0.78 | SHBG (0.39) | CPB2 | |
| SCHEMBL8352329 | 0.78 | CPB2 (0.33) | SMYD3CPB2 | |
| SCHEMBL105388 | 0.78 | CPB2 (0.33) | SMYD3CPB2 | |
| SCHEMBL102088 | 0.78 | CPB2 (0.33) | SMYD3CPB2 | |
| SCHEMBL23128664 | 0.78 | OPRM1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305859-A1 | An Anticonvulsant Compound | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2017-10-26 | — | — | US | claimed |
| EP-3191088-A1 | AN ANTICONVULSANT COMPOUND | Royal Holloway And Bedford New College (GB) | 2017-07-19 | — | — | EP | claimed |
| WO-2016038379-A1 | AN ANTICONVULSANT COMPOUND | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2016-03-17 | — | — | WO | claimed |
| US-10301263-B2 | Anticonvulsant compound | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2019-05-28 | — | — | US | disclosed |
| US-20170305859-A1 | An Anticonvulsant Compound | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2017-10-26 | — | — | US | disclosed |
| EP-3191088-A1 | AN ANTICONVULSANT COMPOUND | Royal Holloway And Bedford New College (GB) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016038379-A1 | AN ANTICONVULSANT COMPOUND | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305859-A1 | An Anticonvulsant Compound | PSEN2, BACE2, APP | SMYD3 3754/4885CPB2 807/4885 |
| US-10301263-B2 | Anticonvulsant compound | PSEN2, BACE2, APP | SMYD3 3651/4885CPB2 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.